Latest filing published 11 Feb 2026 for ELI LILLY & Co, €4.3M.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +77.3%Entry US$577.10 · Close at T+365 US$1,023.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jacob Van Naarden: trading record in brief
In 2018, Jacob Van Naarden filed 138 disclosures, in a record of 192 filings published between August 16, 2017 and February 11, 2026. The 138 sales total EUR 10,132,306, but the median is only EUR 47,320: a flood of small trades, the largest being EUR 450,877 (August 14, 2018), EUR 427,175 (August 13, 2018) and EUR 382,075 (September 13, 2018).
One purchase exists, EUR 552,690 at ELI LILLY & Co on August 13, 2025, or 1% of the open-market trades. The rest is 42 option exercises, 9 share grants and 2 filings of another kind.
Loxo Oncology supplies 176 filings (Chief Business Officer) and ELI LILLY & Co 16 (EVP & Pres., Lilly Oncology). The annual count goes from 37 in 2017 to 138 in 2018, then drops to one in 2019 and in 2022, and to 3 or 4 a year after that. Publication comes a median of 2 days after the trade. Three filings fall in the last twelve months, with neither a sale nor a purchase.
Naarden has 138, 138 and 72 own market trades within 30 days of colleagues at Loxo Oncology, Inc., in that order. All on the same side. In the same order, the colleagues are Jennifer Burstein, Joshua H. Bilenker and Lori Anne Kunkel.
Companies and markets linked to Jacob Van Naarden
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 4,865.888 shares@ US$1,044.6734.7% of flowCommon StockSEC:0001661254-26-000004:0
- 1,909.38 shares@ US$1,037.159.7% of flowCommon StockSEC:0001661254-26-000002:1
- 4,108 shares0Common StockSEC:0001661254-26-000002:0
- 1,000 shares@ US$647.364.5% of flowCommon StockSEC:0000059478-25-000218:0Canonical exit: 11 Nov 2025 (T+90)
- 6,103.824 shares@ US$868.8841.5% of flowCommon StockSEC:0000059478-25-000057:0
- 1,409.84 shares@ US$811.086.5% of flowCommon StockSEC:0000059478-25-000030:1
- 3,023 shares0Common StockSEC:0000059478-25-000030:0
- 4,302 shares0Common StockSEC:0000059478-24-000247:0
- 2,369 shares@ US$737.2613.1% of flowCommon StockSEC:0000059478-24-000058:0
- 1,685 shares@ US$645.615.9% of flowCommon StockSEC:0000059478-24-000015:1
- 3,618 shares0Common StockSEC:0000059478-24-000015:0
- 1,314 shares@ US$335.012.4% of flowCommon StockSEC:0000059478-23-000079:1
- 2,785 shares0Common StockSEC:0000059478-23-000079:0
- 2,407 shares@ US$345.126.2% of flowCommon StockSEC:0000059478-23-000065:0
- 2,186 shares@ US$243.842.8% of flowCommon StockSEC:0000059478-22-000065:1
- 5,461 shares0Common StockSEC:0000059478-22-000065:0
- 19,000 shares@ US$235.0030.2% of flowCommon StockSEC:0001567619-19-004576:0
- 1,000 shares@ US$132.230.9% of flowCommon StockSEC:0001567619-18-007788:2
- 900 shares@ US$133.170.8% of flowCommon StockSEC:0001567619-18-007788:3
- 1,400 shares@ US$134.651.2% of flowCommon StockSEC:0001567619-18-007788:4
- 500 shares@ US$135.140.4% of flowCommon StockSEC:0001567619-18-007788:5
- 200 shares@ US$136.480.2% of flowCommon StockSEC:0001567619-18-007788:6
- 100 shares@ US$137.390.1% of flowCommon StockSEC:0001567619-18-007788:7
- 4,500 shares@ US$13.670.4% of flowCommon StockSEC:0001567619-18-007788:8
- 400 shares@ US$134.740.4% of flowCommon StockSEC:0001567619-18-007788:9
25 of 192 declarations
